Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention

The novel care model will integrate FDA-approved kidneyintelX.dkd™  and Carna Health's digital health platform to identify at-risk patients, halt disease progression, and slash healthcare costs, significantly benefiting US health systems and providers NEW YORK and BOSTON, May 12, 2026 /PRNewswire/ -- Renalytix PLC (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, and Carna Health, an AI-enabled digital health company revolutionizing chronic disease prevention, both leaders in improving outcomes in chronic kidney disease (CKD), today announced a landmark partnership designed to transform how health systems identify, stratify, and manage chronic kidney disease and its interconnected cardiovascular-kidney-metabolic (CKM) complications. By integrating Renalytix's FDA-approved kidneyintelX.dkd test, the gold standard in predicting progressive decline in kidney function in patients with type 2 diabetes and early-stage CKD, with Carna Health's AI-driven prevention and digital care management platform, health systems can benefit from moving beyond traditional detection to risk-guided, personalized care pathways that enable earlier, targeted interventions before patients reach catastrophic, high-cost clinical milestones.